JP2017526695A5 - - Google Patents

Download PDF

Info

Publication number
JP2017526695A5
JP2017526695A5 JP2017512679A JP2017512679A JP2017526695A5 JP 2017526695 A5 JP2017526695 A5 JP 2017526695A5 JP 2017512679 A JP2017512679 A JP 2017512679A JP 2017512679 A JP2017512679 A JP 2017512679A JP 2017526695 A5 JP2017526695 A5 JP 2017526695A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
patient
composition according
anamorelin
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017512679A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017526695A (ja
JP6356907B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/047435 external-priority patent/WO2016036598A1/en
Publication of JP2017526695A publication Critical patent/JP2017526695A/ja
Publication of JP2017526695A5 publication Critical patent/JP2017526695A5/ja
Priority to JP2018113592A priority Critical patent/JP6923486B2/ja
Application granted granted Critical
Publication of JP6356907B2 publication Critical patent/JP6356907B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017512679A 2014-09-04 2015-08-28 アナモレリンに基づく医療 Active JP6356907B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2018113592A JP6923486B2 (ja) 2014-09-04 2018-06-14 アナモレリンに基づく医療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462045976P 2014-09-04 2014-09-04
US62/045,976 2014-09-04
PCT/US2015/047435 WO2016036598A1 (en) 2014-09-04 2015-08-28 Medical treatments based on anamorelin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018113592A Division JP6923486B2 (ja) 2014-09-04 2018-06-14 アナモレリンに基づく医療

Publications (3)

Publication Number Publication Date
JP2017526695A JP2017526695A (ja) 2017-09-14
JP2017526695A5 true JP2017526695A5 (OSRAM) 2017-10-26
JP6356907B2 JP6356907B2 (ja) 2018-07-11

Family

ID=55436476

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017512679A Active JP6356907B2 (ja) 2014-09-04 2015-08-28 アナモレリンに基づく医療
JP2018113592A Active JP6923486B2 (ja) 2014-09-04 2018-06-14 アナモレリンに基づく医療
JP2021029775A Active JP7044918B2 (ja) 2014-09-04 2021-02-26 アナモレリンに基づく医療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018113592A Active JP6923486B2 (ja) 2014-09-04 2018-06-14 アナモレリンに基づく医療
JP2021029775A Active JP7044918B2 (ja) 2014-09-04 2021-02-26 アナモレリンに基づく医療

Country Status (44)

Country Link
US (5) US9675600B2 (OSRAM)
EP (2) EP3188599B1 (OSRAM)
JP (3) JP6356907B2 (OSRAM)
KR (3) KR101881264B1 (OSRAM)
CN (5) CN107375285A (OSRAM)
AP (1) AP2017009772A0 (OSRAM)
AR (1) AR103118A1 (OSRAM)
AU (1) AU2015312231B2 (OSRAM)
BR (1) BR112017003552A2 (OSRAM)
CA (1) CA2959158A1 (OSRAM)
CL (1) CL2017000494A1 (OSRAM)
CO (1) CO2017003263A2 (OSRAM)
CR (1) CR20170121A (OSRAM)
CY (1) CY1122746T1 (OSRAM)
DK (1) DK3188599T3 (OSRAM)
DO (1) DOP2017000055A (OSRAM)
EA (1) EA035578B1 (OSRAM)
EC (1) ECSP17019893A (OSRAM)
ES (1) ES2761777T3 (OSRAM)
GE (1) GEP20186939B (OSRAM)
HR (1) HRP20192345T1 (OSRAM)
HU (1) HUE046894T2 (OSRAM)
IL (1) IL250692B (OSRAM)
JO (1) JO3541B1 (OSRAM)
LT (1) LT3188599T (OSRAM)
MA (1) MA40607B1 (OSRAM)
MD (1) MD4710C1 (OSRAM)
ME (1) ME03597B (OSRAM)
MX (1) MX361741B (OSRAM)
MY (1) MY187167A (OSRAM)
NI (1) NI201700024A (OSRAM)
PE (1) PE20171109A1 (OSRAM)
PH (1) PH12017500392B1 (OSRAM)
PL (1) PL3188599T3 (OSRAM)
PT (1) PT3188599T (OSRAM)
RS (1) RS59751B1 (OSRAM)
SG (1) SG11201701567UA (OSRAM)
SI (1) SI3188599T1 (OSRAM)
SV (1) SV2017005400A (OSRAM)
TN (1) TN2017000040A1 (OSRAM)
TW (1) TWI639429B (OSRAM)
UA (1) UA120765C2 (OSRAM)
UY (1) UY36286A (OSRAM)
WO (1) WO2016036598A1 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9492535B2 (en) 2013-03-14 2016-11-15 Aimmune Therapeutics, Inc. Peanut formulations and uses thereof
HUE046894T2 (hu) 2014-09-04 2020-04-28 Helsinn Healthcare Sa Anamorelinen alapuló gyógyászati kezelések
EP3836801A4 (en) 2018-08-16 2022-05-18 Société des Produits Nestlé S.A. Peanut oral immunotherapy with maintenance dose
CN113891722A (zh) 2018-12-20 2022-01-04 爱沐疗法公司 用于漏服剂量的花生口服免疫疗法给药计划表
EP3965815A4 (en) 2019-05-10 2023-05-31 Société des Produits Nestlé S.A. METHOD OF IMPROVING THE QUALITY OF LIFE IN A PEANUT ALLERGY PATIENT
US20220323430A1 (en) 2019-08-30 2022-10-13 Helsinn Healthcare Sa Methods of manufacturing anamorelin tablets having improved stability
BR112022005457A2 (pt) * 2019-10-24 2022-06-21 Toray Industries Agente terapêutico ou profilático para caquexia
TW202327596A (zh) * 2021-09-17 2023-07-16 瑞士商赫爾辛保健公司 於厭食/惡病體質患者針對患者自述結果判定及提供臨床有意義改善之方法
WO2025004650A1 (ja) * 2023-06-28 2025-01-02 日清オイリオグループ株式会社 中高年者の疲労感を軽減するための剤及び組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303620B1 (en) 1998-05-11 2001-10-16 Novo Nordisk A/S Compounds with growth hormone releasing properties
ECSP993020A (es) 1999-06-16 1999-08-12 Terapia de combinacion para la fragilidad musculoesqueletica
ECSP993021A (es) 1999-06-16 1999-08-12 Combinaciones terapeuticas para la fragilidad musculoesqueletica
US20010020012A1 (en) 2000-02-01 2001-09-06 Andersen Maibritt Bansholm Use of compounds for the regulation of food intake
WO2005014032A2 (en) * 2003-08-06 2005-02-17 Gastrotech Pharma A/S Use of secretagogues like ghrelin in cancer cachexia and for stimulating appetite
CN1863550A (zh) * 2003-08-06 2006-11-15 加斯特罗泰克药物公司 促分泌素样生长素释放肽在癌症恶病质中以及在刺激食欲方面的应用
JP2007531769A (ja) 2004-03-30 2007-11-08 サファイア セラピューティクス インコーポレイテッド 成長ホルモン分泌促進薬を使用したｃ−反応性蛋白質の低減方法
CN1976921B (zh) 2004-06-29 2013-08-21 蓝宝石治疗公司 (3r)-1-(2-甲基丙氨酰-d-色氨酰)-3-(苯甲基)-3-哌啶羧酸1,2,2-三甲基酰肼的晶形
CN101686966A (zh) * 2007-02-13 2010-03-31 赫尔辛医疗（美国）有限公司 使用生长激素促分泌素治疗细胞增生疾病的方法
TWI429436B (zh) * 2007-04-10 2014-03-11 Helsinn Therapeutics Us Inc 使用生長激素促泌素治療或預防嘔吐之方法
JO3353B1 (ar) * 2012-04-20 2019-03-13 Ono Pharmaceutical Co شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي
CN104470524A (zh) 2012-05-25 2015-03-25 拉夸里亚创药株式会社 用于治疗胃酸缺乏症的生长激素释放肽受体激动剂
HUE046894T2 (hu) 2014-09-04 2020-04-28 Helsinn Healthcare Sa Anamorelinen alapuló gyógyászati kezelések

Similar Documents

Publication Publication Date Title
JP2017526695A5 (OSRAM)
JP2019503365A5 (OSRAM)
FI3849534T3 (fi) Yhdistelmähoidot
FI3504187T3 (fi) Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten
MX2021002322A (es) Nuevos metodos.
JP2016528162A5 (OSRAM)
HK1221646A1 (zh) 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途
MX2014013039A (es) Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple.
JP2015505564A5 (OSRAM)
HRP20250615T1 (hr) Tradipitant za upotrebu u liječenju gastropareze
JP2016512817A5 (OSRAM)
HK1202776A1 (en) Use of laquinimod for treating crohn's disease patients who failed first-line anti-tnf therapy
JO3434B1 (ar) مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
JP2018090566A5 (OSRAM)
HRP20192345T1 (hr) Medicinski tretmani na bazi anamorelina
JP2014508758A5 (OSRAM)
MX2020012377A (es) Uso de tabletas de desintegracion orales de riluzol para el tratamiento de enfermedades.
MX2021001563A (es) Uso de tabletas de desintegracion oral de riluzol para tratar enfermedades.
JP2017526693A5 (OSRAM)
MX2022013450A (es) Formulaciones farmaceuticas.
JP2016505050A5 (OSRAM)
MY195178A (en) Composition for Treating Joint Disease and Kit Containing Same
CA3244360A1 (en) Compositions containing MEAI and N-acylethanolamines and their uses
WO2016025671A3 (en) Treatment of sleep apnea with a combination of a carbonic anhydrase inhibitor and an aldosterone antagonist
JP5976923B2 (ja) イリノテカン塩酸塩水和物を含有する抗腫瘍剤